Ginkgo Bioworks Holdings Statistics

Total Valuation

DNA has a market cap or net worth of $669.58 million. The enterprise value is $706.82 million.

Market Cap	669.58M
Enterprise Value	706.82M

Important Dates

The next estimated earnings date is Thursday, August 6, 2026, after market close.

Earnings Date	Aug 6, 2026
Ex-Dividend Date	n/a

Share Statistics

DNA has 65.32 million shares outstanding. The number of shares has increased by 7.30% in one year.

Current Share Class	53.36M
Shares Outstanding	65.32M
Shares Change (YoY)	+7.30%
Shares Change (QoQ)	+4.35%
Owned by Insiders (%)	15.42%
Owned by Institutions (%)	49.42%
Float	47.85M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.42
Forward PS	5.93
PB Ratio	1.43
P/TBV Ratio	1.70
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.67
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.15, with a Debt / Equity ratio of 0.93.

Current Ratio	5.15
Quick Ratio	4.95
Debt / Equity	0.93
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -56.03% and return on invested capital (ROIC) is -19.42%.

Return on Equity (ROE)	-56.03%
Return on Assets (ROA)	-16.16%
Return on Invested Capital (ROIC)	-19.42%
Return on Capital Employed (ROCE)	-31.54%
Weighted Average Cost of Capital (WACC)	8.77%
Revenue Per Employee	$312,163
Profits Per Employee	-$627,614
Employee Count	485
Asset Turnover	0.13
Inventory Turnover	n/a

Taxes

Income Tax	-1.01M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9.98% in the last 52 weeks. The beta is 1.80, so DNA's price volatility has been higher than the market average.

Beta (5Y)	1.80
52-Week Price Change	+9.98%
50-Day Moving Average	8.58
200-Day Moving Average	9.34
Relative Strength Index (RSI)	66.30
Average Volume (20 Days)	1,384,730

Short Selling Information

The latest short interest is 4.56 million, so 6.98% of the outstanding shares have been sold short.

Short Interest	4.56M
Short Previous Month	5.23M
Short % of Shares Out	6.98%
Short % of Float	9.53%
Short Ratio (days to cover)	3.42

Income Statement

In the last 12 months, DNA had revenue of $151.40 million and -$304.39 million in losses. Loss per share was -$5.36.

Revenue	151.40M
Gross Profit	105.42M
Operating Income	-300.76M
Pretax Income	-306.52M
Net Income	-304.39M
EBITDA	-262.49M
EBIT	-300.76M
Loss Per Share	-$5.36

Full Income Statement

Balance Sheet

The company has $373.46 million in cash and $410.70 million in debt, giving a net cash position of -$37.24 million or -$0.57 per share.

Cash & Cash Equivalents	373.46M
Total Debt	410.70M
Net Cash	-37.24M
Net Cash Per Share	-$0.57
Equity (Book Value)	443.15M
Book Value Per Share	7.19
Working Capital	330.36M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$166.22 million and capital expenditures -$1.98 million, giving a free cash flow of -$168.20 million.

Operating Cash Flow	-166.22M
Capital Expenditures	-1.98M
Depreciation & Amortization	38.27M
Net Borrowing	-166,000
Free Cash Flow	-168.20M
FCF Per Share	-$2.57

Full Cash Flow Statement

Margins

Gross margin is 69.63%, with operating and profit margins of -198.65% and -201.05%.

Gross Margin	69.63%
Operating Margin	-198.65%
Pretax Margin	-202.46%
Profit Margin	-201.05%
EBITDA Margin	-173.38%
EBIT Margin	-198.65%
FCF Margin	n/a

Dividends & Yields

DNA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.30%
Shareholder Yield	-7.30%
Earnings Yield	-45.46%
FCF Yield	-25.12%

Analyst Forecast

The average price target for DNA is $8.50, which is -17.07% lower than the current price. The consensus rating is "Hold".

Price Target	$8.50
Price Target Difference	-17.07%
Analyst Consensus	Hold
Analyst Count	3
Revenue Growth Forecast (3Y)	20.32%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on August 20, 2024. It was a reverse split with a ratio of 1:40.

Last Split Date	Aug 20, 2024
Split Type	Reverse
Split Ratio	1:40

Scores

DNA has an Altman Z-Score of -8.32 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.32
Piotroski F-Score	2